Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

State of the Art: Diagnose und Therapie des Multiplen Myeloms

Leo Rasche, Stefan Knop, Hermann Einsele ; Medizinische Klinik II, Abteilung für Hämatologie und Onkologie, Universitätsklinikum Würzburg (S. 9-12)

 

  1. Robert-Koch-Institut, Krebs in Deutschland 2009/2010. 9. Ausgabe, 2013.
  2. Rollig, C., S. Knop, and M. Bornhauser, Multiple myeloma. Lancet, 2015. 385(9983): p. 2197-208.
  3. Weinhold, N., et al., The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet, 2013. 45(5): p. 522-5.
  4. Avet-Loiseau, H., et al., Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myelome experience. J Clin Oncol, 2013. 31(22): p. 2806-9.
  5. Rasche, L., et al., Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol, 2012. 91(7): p. 1031-7.
  6. Rajkumar, S.V., et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol, 2014. 15(12): p. e538-48.
  7. Mateos, M.V., et al., Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med, 2013. 369(5): p. 438-47.
  8. Korde, N., et al., Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncol, 2015.
  9. McCarthy, P.L. and T. Hahn, Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology Am Soc Hematol Educ Program, 2013. 2013: p. 496-503.
  10. Barlogie, B., et al., Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer, 2008. 113(2): p. 355-9.
  11. Attal, M., et al., Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med, 2003. 349(26): p. 2495-502.
  12. Sonneveld, P., et al., Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol, 2012. 30(24): p. 2946-55.
  13. Cavo, M., et al., Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. Blood, 2013. 122(21).
  14. Knop, S., et al., Autologous Followed By Allogeneic Versus TandemAutologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma. Blood, 2014. 124(21).
  15. Knop, S., et al., Up front allogeneic stem cell transplant is superior to tandem high-dose melphalan in cytogenetically defined ultra high-risk myeloma. Onkologie, 2011. 34: p. 199-200.
  16. Kull, M., et al., Outcome and Prognostic Factors of 17p Deleted Multiple Myeloma Patients. Blood, 2014. 124(21).
  17. McCarthy, P.L., et al., The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Expert Rev Hematol, 2014. 7(1): p. 55-66.
  18. Mateos, M.V., et al., Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol, 2015. 90(4): p. 314-9.
  19. Larocca, A., et al., Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. Blood, 2013. 122(21).
  20. Mateos, M.V., et al., Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. Blood, 2014. 124(21).
  21. Richardson, P.G., et al., PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood, 2013. 122(14): p. 2331-7.
  22. Lonial, S., et al., Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med, 2015.

Diagnostik und Therapie des Hodgkin-Lymphoms

Julia Meißner, Universitätsklinikum Heidelberg (S. 14-16)

 

  1. Kuppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, Hansmann ML (1994) Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proceedings of the National Academy of Sciences of the United States of America 91 (23):10962-10966
  2. Swerdlow SN, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. 
  3. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G, European Mantle Cell Lymphoma C, Italian Lymphoma F, European Organisation for R, Treatment of Cancer/Dutch Hemato-Oncology G, Grupo Espanol de Medula O, German High-Grade Lymphoma Study G, German Hodgkin's Study G, Japanese Lymphorra Study G, Lymphoma Study A, Group NCT, Nordic Lymphoma Study G, Southwest Oncology G, United Kingdom National Cancer Research I (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32 (27):3059-3068. doi:10.1200/JCO.2013.54.8800
  4. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Divine M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vie B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M, Trial E-GH (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. The New England journal of medicine 357 (19):1916-1927. doi:10.1056/NEJMoa064601
  5. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sokler M, Ho A, Rank A, Ganser A, Trumper L, Bokemeyer C, Kirchner H, Schubert J, Kral Z, Fuchs M, Muller-Hermelink HK, Muller RP, Diehl V (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. The New England journal of medicine 363 (7):640-652. doi:10.1056/NEJMoa1000067
  6. Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Boll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, German Hodgkin Study G, Swiss Group for Clinical Cancer R, Arbeitsgemeinschaft Medikamentose T (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385 (9976):1418-1427. doi:10.1016/S0140-6736(14)61469-0
  7. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. The New England journal of medicine 372 (17):1598-1607. doi:10.1056/NEJMoa1408648
  8. Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Ferme C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32 (12):1188-1194. doi:10.1200/JCO.2013.51.9298
  9. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin's Lymphoma Study G (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21 (19):3601-3608. doi:10.1200/JCO.2003.03.023
  10. von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A (2012) Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30 (9):907-913. doi:10.1200/JCO.2011.38.5807
  11. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. The New England journal of medicine 327 (21):1478-1484. doi:10.1056/NEJM199211193272102
  12. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dorken B, Muller-Hermelink HK, Duhmke E, Loeffler M, German Hodgkin's Lymphoma Study G (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. The New England journal of medicine 348 (24):2386-2395. doi:10.1056/NEJMoa022473
  13. Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, Borchmann P (2013) Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. The Lancet Oncology 14 (10):943-952. doi:10.1016/S1470-2045(13)70341-3
  14. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Kral Z, Fuchs M, Hallek M, Kanz L, Dohner H, Dorken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Muller RP, Dietlein M, Borchmann P, Diehl V, German Hodgkin Study G, Swiss Group for Clinical Cancer R, Arbeitsgemeinschaft Medikamentose T (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379 (9828):1791-1799. doi:10.1016/S0140-6736(11)61940-5
  15. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341 (8852):1051-1054
  16. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V, German Hodgkin's Lymphoma Study G, Lymphoma Working Party of the European Group for B, Marrow T (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359 (9323):2065-2071. doi:10.1016/S0140-6736(02)08938-9
  17. Josting A, Rudolph C, Mapara M, Glossmann JP, Sieniawski M, Sieber M, Kirchner HH, Dorken B, Hossfeld DK, Kisro J, Metzner B, Berdel WE, Diehl V, Engert A (2005) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 16 (1):116-123. doi:10.1093/annonc/mdi003
  18. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J, Group AS (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385 (9980):1853-1862. doi:10.1016/S0140-6736(15)60165-9
  19. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30 (18):2183-2189. doi:10.1200/JCO.2011.38.0410
  20. Ansell SM (2015) Targeting immune checkpoints in lymphoma. Current opinion in hematology 22 (4):337-342. doi:10.1097/MOH.0000000000000158

Non-Hodgkin-Lymphome bei Kindern: Besonderheiten bei Diagnose und Therapie

Stephanie Müller, Birgit Burkhardt; NHL-BFM Studienzentrale, Universitäts-Kinderklinik Münster, Abteilung Pädiatrische Hämatologie und Onkologie (S. 18-22)

 

  1. Worch J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives. Pediatr Hematol Oncol. 2013;30(6):465-83.
  2. Burkhardt B, Lenz G. Management of paediatric and adult non-Hodgkin lymphoma: what lessons can each teach the other? Hematol Oncol 2015; 33 Suppl 1:62-6.
  3. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-68.
  4. Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol 2015;2112-2118.
  5. Qiu L, Chen Y, Wu J. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.   Hell J Nucl Med 2013;16(3):230-6. 
  6. Schmidt E, Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence.      Pediatr Hematol Oncol 2013; 30(6):484-508.
  7. Balbach ST, Makarova O, Bonn BR, et al. Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia 2015 Jul 28. 
  8. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013; 31(34): 4333–4342.
  9. Cortelazzo S, Intermesoli T, Oldani E, et al. Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. Ann Hematol. 2012;91(1):73-82.
  10. Cortelazzo S, Ponzoni M, Ferreri AJ, et al. Lymphoblastic lymphoma. Crit Rev Oncol Hematol 2011;79(3):330-43.
  11. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999;94(10):3294-306.
  12. Kubuschok B, Held G, Pfreundschuh M. Management of diffuse large B-cell lymphoma (DLBCL). Cancer Treat Res 2015;165:271-88. 
  13. Coiffier B1, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.                                         N Engl J Med 2002; 346(4):235-42.
  14. Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel) 2015;7(1):305-28.
  15. Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 2011;29(22):3065-71. 
  16. Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group.                                          J Clin Oncol 2009;27(6):897-903.
  17. Eyre TA, Khan D, Hall GW, et al. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.                    Eur J Haematol 2014;93(6):455-68. 
  18. Woessmann W. XI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma? Hematol Oncol. 2013;31 Suppl 1:64-8. 
  19. Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol. 2009;27(20):3363-9. 

Aggressive Lymphome – Diagnostik und Therapie

Christian Schmidt, Martin Dreyling, Klinikum der Universität München (S. 23-27)

 

  1. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
  2. Moskowitz CH. Interim PET-CT in the management of diffuse large B-cell lymphoma. ASH Education Program Book. 2012;2012(1):397-401.
  3. Duehrsen U, Hüttmann A, Müller S, et al. Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas – a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial). Vol. 124; 2014.
  4. Weisenburger DD. Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol. 1994;5 Suppl 1:19-24.
  5. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res. 1992;52(19 Suppl):5432s-5440s.
  6. Savage KJ, Zeynalova S, Kansara RR, et al. Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma. Vol. 124; 2014.
  7. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11):1860-1861.
  8. Musshoff K. [Clinical staging classification of non-Hodgkin's lymphomas (author's transl)]. Strahlentherapie. 1977;153(4):218-221.
  9. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
  10. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380.
  11. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Vol. 123; 2014.
  12. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9(5):435-444.
  13. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38(4):1484-1493.
  14. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. The New England journal of medicine. 1993;328(14):1002-1006.
  15. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634-641.
  16. Pfreundschuh M, Ziepert M, Zeynalova S, et al. 7-Year Follow-up of the Ricover-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (Dshnhl). Annals of Oncology. 2011;22:193-193.
  17. Pfreundschuh M, Kloess M, Zeynalova S, et al. Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the completed RICOVER-60 trial of the german high-grade non-Hodgkin lymphoma study group (DSHNHL). Blood. 2006;108(11):64a-65a.
  18. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncology. 2011;12(5):460-468.
  19. Kubuschok B, Held G, Pfreundschuh M. Management of Diffuse Large B-Cell Lymphoma (DLBCL). Cancer Treat Res. 2015;165:271-288.
  20. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20(10):2472-2479.
  21. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336(18):1290-1297.
  22. Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250-1259.
  23. Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. The New England journal of medicine. 2013;369(18):1681-1690.
  24. Waserlid T, Szekely E, Hartman LW, Jerkeman M. R-CHOEP-14 Is Associated with Superior Overall Survival Compared to R-CHOP-21 and R-CHOP-14 in Patients with DLBCL <= 70 Years - a Swedish Lymphoma Registry Population Based Study. Blood. 2014;124(21).
  25. Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncology. 2011;12(11):1013-1022.
  26. Pfreundschuh M, Truemper L, Gill D, et al. First analysis of the completed Mabthera International (MInT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=O and no bulky disease. Blood. 2004;104(11):48a-48a.
  27. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like Than in Germinal Center B-Cell-Like Phenotype. Cancer. 2011;117(22):5058-5066.
  28. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
  29. Wilson WH, Gerecitano JF, Goy A, et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. ASH Annual Meeting Abstracts. 2012;120(21):686-.
  30. Klanova M, Andera L, Soukup J, et al. MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma ( DLBCL) Cells and Synergizes with BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells. Blood. 2014;124(21).

Target-orientierte Wirkstoffe: Monoklonale Antikörper bei gynäkologischen Tumoren

Eva-Maria Grischke, Florin-Andrei Taran, Andreas Hartkopf, Stefan Kommoss, Christina Walter, Sara Brucker; Universitätsfrauenklinik Tübingen (S. 43-48)

 

  1. Baselga J, et al. N Engl J Med 2012; 366:109-119
  2. Verma et al. NEIJM 2012
  3. Stockler et al. J Clin Oncol 2014;32(13):1309 – 16
  4. Burger RA et al. J Clin Oncol 2011;29(Suppl.):337s (Abstract 5023)
  5. Burger RA et al. N Engl J Med 2011;365:2473-2483
  6. Burger RA et al. Ann Oncol 2010;21(Duppl 8): viii 307 (Abstract 978PD)
  7. Aghajanian C et al. J Clin Oncol. 2012:30(17):2039-45
  8. Aghajanian C et al J. Clin Oncol 2012;30 (Suppl 15):(Abstract 5054)
  9. Tewari KS et al. J Clin Oncol 2013; 31(Suppl): Abstract 3
  10. Tewari KS et al. Ann Onc 2014; 25 (suppl 4): mdu438.27, LBA26
  11. Welslau et al. ESMO 2012, Poster 329P.
  12. Spector NL, Blackwell KL. J Clin Oncol 2009;
  13. Nelson MH, et al. ANN Pharmacother 2006;
  14. Richter et al. SABCS 2011#PD-05-05
  15. LoRusso PM, et al. Clin Cancer Res 2011
  16. Verma, S, et al. Trastuzumab Emtansine for Her2-Positive Advanced Breast Cancer. N Engl J Med 367:19; 1783 – 1791 
  17. Swain, S., et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med 372:8; 724 – 734
  18. Gianni, L., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicenter, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25–32
  19. Pujade-Lauraine, E., et al., Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J Clin Oncol 2014, 32: 1302 – 1308
  20. Tewari, K., et al., Improved Survival with Bevacizumab in Advanced Cervical Cancer. N Engl J Med 2014; 370: 734 – 743
  21. Brodowicz, T., et al., Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer 2014; 111: 2051–2057
  22. Miles, D., et al., First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Annals of Oncology 2013; 24: 2773–2780
  23. Fagerholm, R., et al., Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer. Annals of Oncology 2013; 24: 2780–2785
  24. Rugo, H., et al., Randomized Phase III Trial of Paclitaxel Once Per Week Compared with nanoparticle Albumin-Bound Nab-Paclitaxel once per Week or Ixabepilone with Bevacizumab as First-line Chemotherapy for locally recurrent or metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 2015; 33